Figure 6 : FPR agonist Cmpd17b reduces systemic inflammation 48 h-post I–R injury.

From: Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice

Figure 6

Circulating levels of (a) total WBCs, (b) lymphocytes, (c) neutrophils, (d) monocytes and (e) IL-1β in sham, vehicle- and FPR agonist-treated (Cmpd17b or Cmpd43, both 50 mg kg−1 per day, i.p.) mice after 48 h reperfusion. Results are expressed as mean±s.e.m. #P<0.05, ##P<0.01 versus sham,*P<0.05 versus vehicle-treated mice on one-way ANOVA with Dunnett’s post hoc test (n, number of mice per group, indicated below the x axis). Shams (open bars); I–R (black bars); Cmpd17b (blue bars); Cmpd43 (red bars).